INHA and tuberculosis: The combined results unambiguously indicate that pyridomycin is a competitive inhibitor of the NADH-binding site of InhA, NADH-dependent enoyl-[Acyl-Carrier-Protein] reductase, the target of the two anti-tuberculosis pro-drugs isoniazid and ethionamide (Banerjee et al, 1994; Vilcheze et al, 2006).